Hyperbilirubinemia in Preterm Neonates

Clinics in Perinatology

Volumn 43, Issue 2, 2016, Pages 215-232

  Bhutani, Vinod K ^a   Wong, Ronald J ^a   Stevenson, David K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant properties; Bilirubin; BIND; Photosensitivity; Reactive oxygen species

Indexed keywords

BILIRUBIN; IMMUNOGLOBULIN; METALLOPORPHYRIN; PHENOBARBITAL;

BIRTH WEIGHT; BLOOD GROUP ABO INCOMPATIBILITY; EXCHANGE BLOOD TRANSFUSION; EXCITOTOXICITY; GESTATIONAL AGE; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; JAUNDICE; KERNICTERUS; NEUROTOXICITY; NEWBORN; NEWBORN HEMOLYTIC DISEASE; NEWBORN JAUNDICE; NEWBORN MORTALITY; OTOTOXICITY; PERCEPTION DEAFNESS; PHOTOTHERAPY; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VESTIBULOCOCHLEAR NERVE DISEASE; VISUAL EVOKED POTENTIAL; COMPLICATION; HYPERBILIRUBINEMIA, NEONATAL; PROCEDURES; RISK ASSESSMENT; TIME FACTOR;

GESTATIONAL AGE; HUMANS; HYPERBILIRUBINEMIA, NEONATAL; INFANT, NEWBORN; INFANT, PREMATURE; KERNICTERUS; PHOTOTHERAPY; RISK ASSESSMENT; TIME FACTORS;

EID: 84962481330     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2016.01.001     Document Type: Review

References (81)

1. American Academy of Pediatrics Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004, 114:297-316.
2. Bhutani V.K., Johnson L., Sivieri E.M. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999, 103:6-14.
3. Johnson L., Bhutani V.K., Karp K., et al. Clinical report from the pilot USA kernicterus registry (1992 to 2004). J Perinatol 2009, 29(Suppl 1):S25-S45.
4. Bhutani V.K., Johnson L.H., Shapiro S.M. Kernicterus in sick and preterm infants (1999-2002): a need for an effective preventive approach. Semin Perinatol 2004, 28:319-325.
5. Bhutani V.K., Vilms R.J., Hamerman-Johnson L. Universal bilirubin screening for severe neonatal hyperbilirubinemia. J Perinatol 2010, 30(Suppl):S6-S15.
6. Watchko J.F., Oski F.A. Kernicterus in preterm newborns: past, present, and future. Pediatrics 1992, 90:707-715.
7. Broman S.H., Nicholas P.I., Kennedy W.A. Preschool IQ: prenatal and early developmental correlates 1975, Lawrence Erlbaum Associates, Hillsdale (NJ).
8. Johnson L., Bhutani V.K. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol 2011, 35:101-113.
9. Scheidt P.C., Graubard B.I., Nelson K.B., et al. Intelligence at six years in relation to neonatal bilirubin levels: follow-up of the National Institute of Child Health and Human Development Clinical Trial of Phototherapy. Pediatrics 1991, 87:797-805.
10. Bhutani V.K., Wong R.J. Bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med 2015, 20:1-64.
11. Bhutani V.K., Zipursky A., Blencowe H., et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013, 74(Suppl 1):86-100.
12. Crosse V.M., Meyer T.C., Gerrard J.W. Kernicterus and prematurity. Arch Dis Child 1955, 30:501-508.
13. Oh W., Stevenson D.K., Tyson J.E., et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010, 99:673-678.
14. Brodersen R. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest 1974, 54:1353-1364.
15. Morris B.H., Oh W., Tyson J.E., et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008, 359:1885-1896.
16. Oh W., Tyson J.E., Fanaroff A.A., et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003, 112:773-779.
17. O'Shea T.M., Dillard R.G., Klinepeter K.L., et al. Serum bilirubin levels, intracranial hemorrhage, and the risk of developmental problems in very low birth weight neonates. Pediatrics 1992, 90:888-892.
18. Yeo K.L., Perlman M., Hao Y., et al. Outcomes of extremely premature infants related to their peak serum bilirubin concentrations and exposure to phototherapy. Pediatrics 1998, 102:1426-1431.
19. Lamola A.A., Bhutani V.K., Du L., et al. Neonatal bilirubin binding capacity discerns risk of neurological dysfunction. Pediatr Res 2015, 77:334-339.
20. Ahdab-Barmada M., Moossy J. The neuropathology of kernicterus in the premature neonate: diagnostic problems. J Neuropathol Exp Neurol 1984, 43:45-56.
21. Jardine D.S., Rogers K. Relationship of benzyl alcohol to kernicterus, intraventricular hemorrhage, and mortality in preterm infants. Pediatrics 1989, 83:153-160.
22. Bhutani V.K., Johnson L.H., Jeffrey Maisels M., et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004, 24:650-662.
23. Johnson L.H., Bhutani V.K., Brown A.K. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002, 140:396-403.
24. Bhutani V.K., Stark A.R., Lazzeroni L.C., et al. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr 2013, 162:477-482.e1.
25. Shapiro S.M. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med 2010, 15:157-163.
26. Perlstein M. Neurologic sequelae of erythroblastosis fetalis. Am J Dis Child 1950, 79:605-606.
27. Van Praagh R. Diagnosis of kernicterus in the neonatal period. Pediatrics 1961, 28:870-876.
28. Volpe J.J. Bilirubin and brain injury. Neurology of the newborn 2000, 490-514. W.B. Saunders, Philadelphia. 2nd edition. J.J. Volpe (Ed.).
29. Bhutani V.K., Wong R.J. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol 2013, 2:61-69.
30. Brodersen R., Stern L. Deposition of bilirubin acid in the central nervous system-a hypothesis for the development of kernicterus. Acta Paediatr Scand 1990, 79:12-19.
31. Walker P.C. Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement. Clin Pharmacokinet 1987, 13:26-50.
32. De Vries L.S., Lary S., Whitelaw A.G., et al. Relationship of serum bilirubin levels and hearing impairment in newborn infants. Early Hum Dev 1987, 15:269-277.
33. Berlin C.I., Hood L.J., Morlet T., et al. Multi-site diagnosis and management of 260 patients with auditory neuropathy/dys-synchrony (auditory neuropathy spectrum disorder). Int J Audiol 2010, 49:30-43.
34. Chisin R., Perlman M., Sohmer H. Cochlear and brain stem responses in hearing loss following neonatal hyperbilirubinemia. Ann Otol 1979, 88:352-357.
35. Bielecki I., Horbulewicz A., Wolan T. Prevalence and risk factors for auditory neuropathy spectrum disorder in a screened newborn population at risk for hearing loss. Int J Pediatr Otorhinolaryngol 2012, 76:1668-1670.
36. Hou C., Norcia A.M., Madan A., et al. Visuocortical function in infants with a history of neonatal jaundice. Invest Ophthalmol Vis Sci 2014, 55:6443-6449.
37. Amin S.B., Bhutani V.K., Watchko J.F. Apnea in acute bilirubin encephalopathy. Semin Perinatol 2014, 38:407-411.
38. Govaert P., Lequin M., Swarte R., et al. Changes in globus pallidus with (pre)term kernicterus. Pediatrics 2003, 112:1256-1263.
39. Ahlfors C.E. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994, 93:488-494.
40. Khwaja O., Volpe J.J. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 2008, 93:F153-F161.
41. Rutherford M.A., Supramaniam V., Ederies A., et al. Magnetic resonance imaging of white matter diseases of prematurity. Neuroradiology 2010, 52:505-521.
42. Stocker R., Yamamoto Y., McDonagh A.F., et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
43. Fischman D., Valluri A., Gorrepati V.S., et al. Bilirubin as a protective factor for rheumatoid arthritis: an NHANES study of 2003-2006 data. J Clin Med Res 2010, 2:256-260.
44. Takamatsu N., Abe H., Tominaga T., et al. Risk factors for chronic kidney disease in Japan: a community-based study. BMC Nephrol 2009, 10:34.
45. Yamamoto R., Kanazawa A., Shimizu T., et al. Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2009, 84:39-45.
46. Chen Y.H., Hung S.C., Tarng D.C. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:567-574.
47. Fukui M., Tanaka M., Yamazaki M., et al. Low serum bilirubin concentration in haemodialysis patients with type 2 diabetes. Diabet Med 2011, 28:96-99.
48. Riphagen I.J., Deetman P.E., Bakker S.J., et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 2014, 63:2845-2853.
49. Tanaka M., Fukui M., Okada H., et al. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 2014, 234:421-425.
50. Oda E., Aoyagi R., Aizawa Y. Hypobilirubinemia might be a possible risk factor of end-stage kidney disease independently of estimated glomerular filtration rate. Kidney Blood Press Res 2012, 36:47-54.
51. Chin H.J., Cho H.J., Lee T.W., et al. The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci 2009, 24(Suppl):S22-S29.
52. Dvorakova H.M., Szitanyi P., Dvorak P., et al. Determinants of premature atherosclerosis in children with end-stage renal disease. Physiol Res 2012, 61:53-61.
53. Boon A.C., Bulmer A.C., Coombes J.S., et al. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol 2014, 307:F123-F136.
54. Wagner K.H., Wallner M., Molzer C., et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond) 2015, 129:1-25.
55. Bulmer A.C., Blanchfield J.T., Toth I., et al. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008, 199:390-396.
56. Neuzil J., Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994, 269:16712-16719.
57. Stocker R., Peterhans E. Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun 1989, 6:57-66.
58. do Sameiro-Faria M., Kohlova M., Ribeiro S., et al. Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis. Biomed Res Int 2014, 2014:175286.
59. Brites D., Brito A. Bilirubin toxicity. Neonatal jaundice 2012, 115-143. The McGraw Hill Companies, New York. D.K. Stevenson, M.J. Maisels, J.F. Watchko (Eds.).
60. Hansen T.W. Prevention of neurodevelopmental sequelae of jaundice in the newborn. Dev Med Child Neurol 2011, 53(Suppl 4):24-28.
61. Watchko J.F., Tiribelli C. Bilirubin-induced neurologic damage. N Engl J Med 2014, 370:979.
62. Maisels M.J., Watchko J.F., Bhutani V.K., et al. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012, 32:660-664.
63. Schulz S., Wong R.J., Vreman H.J., et al. Metalloporphyrins-an update. Front Pharmacol 2012, 3:68.
64. Brown A.K., Kim M.H., Wu P.Y., et al. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985, 75:393-400.
65. Vreman H.J., Wong R.J., Stevenson D.K. Phototherapy: current methods and future directions. Semin Perinatol 2004, 28:326-333.
66. Bhutani V.K., Fetus and Newborn, American Academy of Pediatrics Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011, 128:e1046-e1052.
67. Murki S., Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. Semin Perinatol 2011, 35:175-184.
68. Drummond G.S., Kappas A. Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol 2004, 28:365-368.
69. Maisels M.J., Bhutani V.K., Bogen D., et al. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. Pediatrics 2009, 124:1193-1198.
70. Rübo J., Albrecht K., Lasch P., et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992, 121:93-97.
71. Okuda H., Potter B.J., Blades B., et al. Dose-related effects of phenobarbital on hepatic glutathione-S-transferase activity and ligandin levels in the rat. Drug Metab Dispos 1989, 17:677-682.
72. Wallin A., Boreus L.O. Phenobarbital prophylaxis for hyperbilirubinemia in preterm infants. A controlled study of bilirubin disappearance and infant behavior. Acta Paediatr Scand 1984, 73:488-497.
73. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 1968, 61:748-755.
74. Wong R.J., Vreman H.J., Schulz S., et al. In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins. J Perinatol 2011, 31(Suppl 1):S35-S41.
75. Gourley G.R. Breast-feeding, neonatal jaundice and kernicterus. Semin Neonatol 2002, 7:135-141.
76. Hintz S.R., Stevenson D.K., Yao Q., et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?. Acta Paediatr 2011, 100:960-965.
77. Ahlfors C.E., Wennberg R.P., Ostrow J.D., et al. Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Clin Chem 2009, 55:1288-1299.
78. Funato M., Tamai H., Shimada S., et al. Vigintiphobia, unbound bilirubin, and auditory brainstem responses. Pediatrics 1994, 93:50-53.
79. Amin S.B., Ahlfors C., Orlando M.S., et al. Bilirubin and serial auditory brainstem responses in premature infants. Pediatrics 2001, 107:664-670.
80. Cashore W.J., Oh W. Unbound bilirubin and kernicterus in low-birth-weight infants. Pediatrics 1982, 69:481-485.
81. Ritter D.A., Kenny J.D., Norton H.J., et al. A prospective study of free bilirubin and other risk factors in the development of kernicterus in premature infants. Pediatrics 1982, 69:260-266.